Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 341

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 341
---

future viability is dependent on its ability to raise cash from financing activities to finance its development plans until commercialisation,
generate cash from operating activities and to successfully obtain regulatory approval to allow marketing of its development products.
The Group’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue
its business strategies.

The Group's consolidated
financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of
liabilities in the normal course of business.

As at June 30,
2024, the Group had cash and cash equivalents of £5.06 million. The Directors forecast that the Group currently has enough cash
to fund its planned operations into the first quarter of 2025. If the Company does not secure additional funding before the first quarter
of 2025, it will no longer be a going concern and would likely be placed in Administration.

The Directors have
prepared cash flow forecasts and considered the cash flow requirement for the Group for the next three years including the period 12 months
from the date of approval of this interim financial information. These forecasts show that further financing will be required before the
first quarter of 2025 assuming, inter alia, that certain development programs and other operating activities continue as currently planned.
If we raise additional funds through the issuance of debt securities or additional equity securities, it could result in dilution to our
existing shareholders, increased fixed payment obligations and these securities may have rights senior to those of our ordinary shares
(including the ADSs) and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as
limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights
and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly
harm our business, financial condition and prospects.

| F-6 |

On August 27, 2024,
the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising that the Company
was not in compliance with the minimum bid requirement set forth in NASDAQ’s rules for continued listing of its securities. The
Company has requested a Hearing Panel which has paused any suspension or delisting action pending the hearing. If the Company's ADSs are
delisted, it could be more difficult to buy or sell the Company's ADSs or to obtain accurate quotations, and the price of the Company's